Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
MAGNESIUM SULFATE vs MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
1 g IV every 8 hours infused over 15-30 minutes; dose range 0.5-2 g every 8 hours depending on infection severity
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
1.0–1.5 hours in healthy adults; prolonged to 4–6 hours in moderate renal impairment (CrCl 30–50 mL/min) and 8–12 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: ~70% unchanged via glomerular filtration and tubular secretion; hepatic metabolism: ~20% via hydrolysis of beta-lactam ring; fecal: <2%.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."